• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Making the Rounds of the Microcaps

Conferences' small companies can hold big opportunities.
By JIM COLLINS
Jun 01, 2015 | 12:00 PM EDT
Stocks quotes in this article: ACU, CAB, WMT, TRUU, OHGI, EYES, AMNL, NEWT, CUBI

Following up on my previous column, here are updates from my meetings with CEOs at the Marcum Microcap conference in New York. As a bonus, I added quick previews for a few of the companies with whom I will have private meetings at the LD Micro Conference this week in LA.

Acme United (ACU)

ACU continues to drive growth (sales rose 19% in the first quarter 2015) with innovative niche products. CEO Walter Johnsen always has a hot product to discuss when we meet, and this time it was Cuda fishing knives and tools. With products using German stainless steel, retail availability at places like Bass Pro Shops, Cabela's (CAB) and Wal-Mart (WMT), and a host of celebrity (in the fishing world, anyway) endorsers, I'm guessing Cuda will be a hot product for fishing season.

True Drinks Holdings (TRUU)

CEO Lance Leonard has shepherded TRUU through a period in which the company had insufficient working capital to fulfill large orders from warehouse clubs like Sam's while maintaining existing customers. Raising $4.5 million from Silicon Valley player Vinny Smith and his Toba Capital have cured TRUU's financing issues. TRUU now has zero debt and Smith controls more than 40% of the shares. Now TRUU can fully execute on its plan to grow awareness of its Aquaball product, a sugar-free beacon of healthy hydration in a kids' drink market full of sugary junk. It's time for Leonard to get the message out and get TRUU to cash flow break-even in the third quarter, as he has predicted.

Lomiko Metals

CEO Paul Gill has assembled a very interesting play on graphite/graphene. Graphene, as you've probably read, is a key raw material for 3D-printed applications. Lomiko owns interests in graphite mines, but also stakes in graphene producer Graphene Labs and its related superconductor start-up Graphene ESD. So they're present at both ends of the value chain, and the key is the conducive properties of graphene, which could allow 3D-printed materials to replace many applications that currently use costlier and heavier metals. Trading at a princely 4 cents per share on the OTC, Lomiko shares represent a low-cost way to buy a call-option on the uptake of 3D printing.

One Horizon Group (OHGI)

CEO Brian Collins was undoubtedly the star of Wednesday's sessions, as OHGI shares rose 168% -- a huge move even by microcap standards -- at one point. OHGI issued a release Wednesday morning noting that its Aishuo app had been downloaded 3.5 million times in China since its launch in late February. Also, crucially, OHGI announced that Aishuo is now able to accept Union Pay, Alipay and WeChat Wallet. The path to monetization for OHGI's premium mobile VoIP services in China is complete.

I'll be highlighting the following points in my meetings with the relevant managements at LD Micro:

Second Sight Medical Products (EYES): I was the first to publish financial research on EYES on the day of its IPO in November, and I am no less convinced in the game-changing nature of its Argus II retinal implant. At this point, it's a matter of day-to-day execution on Argus II, and my conversation with CEO Bob Greenberg will focus on worldwide growth in implanting centers, winning approvals from regional Medicare administrative contractors, and the nuts-and-bolts details of bringing sight to the sightless.

Applied Minerals (AMNL): Like Lomiko, Applied Minerals is really a play on uptake of a material -- halloysite clay in AMNL's case -- which has a broad range of weight-saving and strength-enhancing potential commercial applications.

Newtek (NEWT)/Customers Bancorp (CUBI): Both companies are at the cutting edge of the economy, with a focus on small business lending. With so much noise coming from the Bureau of Economic Analysis and its ridiculously volatile GDP readings, it's hard to know exactly how the U.S. economy is faring. Thus, it's incredibly helpful to talk to managements at NEWT and CUBI and get the view from the front lines.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Collins was long EYES and TRUU, although positions may change at any time.

You should be aware that microcap stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information, and that postings such as this one can have an effect on their stock prices.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

Moderna Now Looks Like an Effective Long Trade With Few Side Effects

Bruce Kamich
Jan 14, 2021 12:06 PM EST

MRNA has corrected its big November rally and now looks ready to start a fresh advance, according to the charts.

Pacific Biosciences Reaches Our Price Target: Now What?

Bruce Kamich
Jan 13, 2021 12:19 PM EST

Let's check out the charts and technical indicators.

Emergent BioSolutions Is Looking Stronger

Bruce Kamich
Jan 12, 2021 10:37 AM EST

Here's an update on EBS shares.

Danaher Could Trade Higher

Bruce Kamich
Jan 11, 2021 2:50 PM EST

I do not find enough technical reasons to recommend new long positions at this point in time.

Here's Why Eli Lilly Broke to the Upside

Bruce Kamich
Jan 11, 2021 1:00 PM EST

Let's review the charts and indicators.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    When it's time to sell, will you act or freeze?
  • 08:35 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 1/13/2021

    Lower highs... SPX (Long-Term View) The 1/8/2...
  • 08:07 AM EST GARY BERMAN

    Tuesday Morning Fibocall for 1/12/2021

    Watch if the recent trend of lower highs continues...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login